Related Experiment Video

Updated: Feb 11, 2026

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K

Synergistic Activation of NO and Cytokine Production by TLR3 With TLR5 or TLR7 Agonists in RAW 264.7 Cells

Thu-Dung Doan1,2, Haroon Afzal1, Asad Murtaza1,3

  • 1International Degree Program in Animal Vaccine Technology, National Pingtung University of Science and Technology, Pingtung, Taiwan.

Microbiology and Immunology
|February 10, 2026
PubMed

Insights

This study shows that combining Toll-like receptor (TLR) ligands, specifically Poly(I:C) and imiquimod, significantly boosts nitric oxide and cytokine production in macrophages. This synergistic effect enhances immune responses, offering potential for vaccine adjuvants and cancer immunotherapy.

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Biology

Background:

  • Macrophages are crucial innate immune cells.
  • Toll-like receptors (TLRs) recognize pathogen patterns, initiating immune responses.
  • TLR3, TLR5, and TLR7 ligands activate distinct signaling pathways.

Purpose of the Study:

  • To investigate the effects of TLR3 (Poly(I:C)), TLR5 (Flagellin), and TLR7 (Imiquimod) ligands on macrophage activation.
  • To explore the individual and combined impacts of these TLR ligands on nitric oxide (NO) and pro-inflammatory cytokine production.
  • To elucidate the synergistic interactions between TLR signaling pathways.

Main Methods:

  • RAW 264.7 mouse macrophage cells were stimulated with individual and combined TLR ligands.
  • Nitric oxide (NO) production was measured.
  • Pro-inflammatory cytokine expression (IL-12p40, IFN-γ, TNF-α, IL-6) was analyzed.
  • TRIF-dependent and MyD88-dependent signaling pathways were assessed.

Main Results:

  • All tested TLR agonists individually induced NO production and cytokine expression.
  • Co-stimulation with Poly(I:C) and imiquimod demonstrated significant synergistic enhancement of NO production.
  • A robust upregulation of Th1-type (IL-12p40, IFN-γ, TNF-α) and Th2-type (IL-6) cytokines was observed.
  • Optimal synergy for cytokine induction occurred at specific concentrations of Poly(I:C) and imiquimod.

Conclusions:

  • Synergistic TLR ligand combinations, particularly Poly(I:C) and imiquimod, potently amplify immune activation.
  • This synergy involves crosstalk between TRIF-dependent (TLR3) and MyD88-dependent (TLR7, TLR5) pathways.
  • These findings suggest potential applications for synergistic TLR agonists as vaccine adjuvants and in cancer immunotherapy.
Keywords:
Poly(I:C)cancer vaccinesflagellinimiquimodimmunostimulantligandssynergismtoll‐like receptor

More Related Videos

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

9.9K
Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production08:32

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production

Published on: March 2, 2014

11.0K

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.2K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.0K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Eukaryotic Transcription Activators02:42

Eukaryotic Transcription Activators

Transcription activators are proteins that promote the transcription of genes from DNA to RNA. In most cases, these proteins contain two separate domains ‒ a domain that binds to DNA and a domain for activating transcription; however, in some cases, a single domain is responsible for both binding and activation of transcription, as seen in the glucocorticoid receptor and MyoD.
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
12.9K